IMFINZI® (durvalumab) significantly improved overall survival and
https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-significantly-improved-overall-survival-and-progression-free-survival-for-patients-with-limited-stage-small-cell-lung-cancer-in-adriatic-phase-III-trial.html
WEBApr 5, 2024 · IMFINZI is also the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after CRT based on the PACIFIC Phase III trial. IMPORTANT SAFETY INFORMATION.
DA: 9 PA: 72 MOZ Rank: 55